Nuwellis Inc vs S&P Global Inc — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while S&P Global Inc trades at $403.75 (market cap $116.50B). The key difference: S&P Global Inc is far larger — about 52954.5× Nuwellis Inc's market cap, and S&P Global Inc pays a 0.98% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and S&P Global Inc for 123 Days on average.
| NUWE | SPGI | |
|---|---|---|
Market Cap | $2.20M | $116.50B |
Volume | 121,544 | 1,430,714 |
Sector | Health | Financials |
52-Week High | $146.65 | $517.92 |
52-Week Low | $0.68 | $370.42 |
Typical Hold Time | 26 Days | 123 Days |
Enterprise Value | -$1.52M | $127.99B |
Dividend Yield | — | 0.98% |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
S&P Global (SPGI) trades at $402.73, up 1.67% with strong analyst support showing 85.7% buy ratings and a $509.50 consensus price target. The stock faces technical headwinds with bearish moving averages but maintains robust fundamentals including 30.5% net margins and consistent revenue growth from $15.3B to $16.1B projected for 2026. Recent developments include expansion into digital asset risk assessment and the acquisition of OpenZeppelin, positioning the company for AI-driven growth across its financial services divisions.
The outlook remains positive given S&P Global's dominant market position and margin expansion potential, though investors should monitor debt levels increasing to 23.3% of assets. Near-term catalysts include Q3 2026 earnings on October 27, with the stock offering 26% upside to analyst targets despite current technical weakness suggesting potential entry points near $391 support.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →